The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis;Romatoid artrit'li hastalarda etanercept ile yapilan anti-tümör nekroz faktör (TNF)-alfa tedavisinin endotel fonksiyonlari üzerine etkisi

Anadolu Kardiyoloji Dergisi

Volumn 10, Issue 2, 2010, Pages 98-103

  Tikiz, Hakan ^a   Arslan, Özlem ^b   Pirildar, Timur ^a   Tikiz, Canan ^a   Bayindir, Petek ^c  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b Departments of Cardiology   (Turkey)

^c EGE UNIVERSITY   (Turkey)

Author keywords

Endothelial function; Etanercept; Rheumatoid arthritis; Tumor necrosis factor alpha

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTERY DIAMETER; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; RHEUMATOID ARTHRITIS; TREATMENT DURATION; VASODILATATION; BLOOD; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION;

EID: 77952504512     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2010.031     Document Type: Article

References (28)

1. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional risk factors. Arthritis Rheum 2001; 44: 2737-45.
2. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 1997; 24: 445-51.
3. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 640-4.
4. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26.
5. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999; 100: 2124-6.
6. Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD. Accelerated atherogenesis in autoimmune rheumatic disease. Autoimmun Rev 2002; 1: 338-47.
7. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63: 31-5.
8. Gonzalez-Juanatey C, Testa A, Garcia-Castello A, Garcia-Porrua C, Llorca J, Vidan J, et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-52.
9. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Mäimattila S, Taskinen MR, Yki-Jävinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002; 22: 1637-41.
10. Yki-Jävinen H, Bergholm R, Leirisalo-Repo M. Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 630-4.
11. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature s associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984-92.
12. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
13. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
14. Feldman M, Maini RN. Anti-TNF-alfa therapy of rheumatoid arthiritis: What have we learned? Ann Rev Immunol 2001; 163: 196-8.
15. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A.Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008; 17: 52-78.
16. Haensel S, Laessig G, Pistrosch F, Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003; 170: 177-80.
17. Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-〈 treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
18. Gonzalez-Juanatey C, Testa A, Garcia-Castello A, Garcia-Porrua C, Llorca J, A. Gonzalez-Gay M. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor-α antibody. Arthritis Rheum 2004; 51: 447-50.
19. Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol 2008; 27: 833-9.
20. Bilsborough W, Keen H, Taylor A, O'Driscoll GJ, Arnolda L, Green DJ. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 2006; 26; 1125-31.
21. Cardillo C, Schinzari F, Mores N, Mettimano M, Melina D, Zoli A, et al. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 2006; 80: 275-81.
22. Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003; 48: 72-80.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of the rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
24. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
25. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74: 247-53.
26. Wong M, Toh J, Wilson A, Rowley K, Karschimkus C, Prior D, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003; 48: 81-9.
27. Landewe RB, van der Borne BE, Breedveld FC, Dijkmans BA. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000; 355: 1616-7.
28. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.